Author Archives: Juliane Böhm

New Hope for Patients with Advanced Endometrial Carcinoma

A new study by Karyopharm Therapeutics offers promising results for women with advanced or recurrent TP53 wild-type endometrial carcinoma. The SIENDO study, presented at the ASCO Annual Meeting 2024, investigates the effect of Selinexor as maintenance therapy.

Study Results:

Progression-Free Survival (PFS): Patients who received Selinexor showed a median PFS of 28.4 months compared to 5.2 months in the placebo group.
Specific Subgroups: For TP53 wild-type/pMMR patients, the median PFS was 39.5 months (Selinexor) vs. 4.9 months (placebo).
Quality of Life: The Q-TWiST analysis showed a significant improvement in quality of life and duration in Selinexor-treated patients.

Safety: No new safety signals were observed. The most common side effects were mild to moderate nausea, vomiting, and diarrhea.

Dr. Reshma Rangwala of Karyopharm emphasizes that these results could position Selinexor as a potential new standard maintenance therapy. A further Phase 3 study will follow to confirm these promising results.

For more information and details on the study, please visit the Karyopharm website here.

Cancer Podcast for Physicians – Endometrial Carcinoma – a Tumor with an Increasing Incidence

Cancer Podcast for Physicians – Endometrial Carcinoma –
a Tumor with an Increasing Incidence

New episode: the cancer podcast with Dr. med. Robert Armbrust and Prof. Dr. med. Dr. h.c. Jalid Sehouli. The discussion focuses on endometrial carcinoma – a tumor with an increasing incidence.

This podcast episode is specifically for physicians.

Listen now:
https://www.krebs-podcast.de/podcasts/endometriumkarzinom-ein-tumor-mit-steigender-inzidenz/

Endometrial Cancer: What is the best therapy today? What are the latest studies? Lecture by Dr. Robert Armbrust

Endometrial Cancer: What is the best therapy today?
What are the latest studies? Lecture by Dr. Robert Armbrust

As part of the 2023 Study Day, Dr. Robert Armbrust from Charité Berlin will give a presentation on the best therapies and latest clinical trials for endometrial cancer.

The Study Day for patients and relatives took place on February 7, 2023, and was an event organized by the German Ovarian Cancer Foundation, the Gyn Study Portal, and the Forum Gyn Oncology in cooperation with: NOGGO e.V., German Sarcoma Foundation, AGO Study Group, European Competence Center for Ovarian Cancer, Survivorship Clinic, Institute for Clinical Cancer Research, Gynecological Cancers Germany e.V., MammaMia!, Yes we can!cer, Thea-App, Focus Me-App, and Das K-Wort. With support from: AstraZeneca, MSD, Pharmamar, and Roche.